The hypotensive action of atenolol has been studied in a randomized double-blind crossover comparison. Twelve patients showed a highly significant reduction in average supine systolic and diastolic blood pressures from pre-treatment values of 196-3/115-9 to 159-1/89-2 mmHg (26'1/15-4 kPa to 22'2/11F9 kPa) after 2 weeks on once daily atenolol. No dose-related reduction in blood pressure was seen and the single 100 mg daily dose was as effective as 100 mg twice daily or 50 mg twice daily. Blood pressures recorded after 2 weeks' atenolol were lower than those obtained at 7 days irrespective of dose.
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Summary The hypotensive action of atenolol has been studied in a randomized double-blind crossover comparison. Twelve patients showed a highly significant reduction in average supine systolic and diastolic blood pressures from pre-treatment values of 196-3/115-9 to 159-1/89-2 mmHg (26'1/15-4 kPa to 22'2/11F9 kPa) after 2 weeks on once daily atenolol. No dose-related reduction in blood pressure was seen and the single 100 mg daily dose was as effective as 100 mg twice daily or 50 mg twice daily. Blood pressures recorded after 2 weeks' atenolol were lower than those obtained at 7 days irrespective of dose.
series, atenolol or 4-(2-hydroxy-3-isopropylaminopropoxy)phenylacetamidej shows relative cardioselectivity (Barrett et al., 1973) and has a half-life of 6-9 hr (Conway et al., 1976) . In view of the latter the authors have investigated the possibility of using this drug on a once daily basis in hypertension. of hypertension, including uraemia or grades III and IV retinopathy. None of the patients gave a history of airways obstruction or heart failure. The study was approved by the local Ethical SubCommittee and all patients freely gave their informed consent.
The duration of the trial was 12 weeks during which the patients were seen at weekly intervals. In the first 2 weeks all received placebo tablets twice daily. Thereafter, they were given 'identical' tablets containing either atenolol 50 mg b.d. (a), atenolol 100 mg b.d. (b), or atenolol 100 mg once daily and placebo tablet once daily (c) for a period of 2 weeks. Each 2-week period of active therapy was followed by a fortnight's 'washout' period in which placebo tablets were taken twice daily ( Table 2) . The order of the 3 active treatments a, b and c was randomized. A symptomatic enquiry was made by JRED or CMC at each visit and an independent observer (CFG) took duplicate readings of blood pressure, supine (after 5 min) and standing (2 min) with a Hawksley random-zero sphygmomanometer and measured heart rate.
The first six patients were seen before noon on each occasion and were instructed not to take their morning dose until after their clinic visit: this ensured that when on schedule c they had not received atenolol for about 28 hours. However owing to re-scheduling of the hypertension clinic the remaining patients were seen in the afternoon: during schedule c these patients received atenolol (100 mg) 18-19 hr before having their blood pressure recorded. Average values of systolic and diastolic blood pressure taken during the various treatment schedules were compared using Student's f-test for paired data.
Results
Twelve of the fourteen patients completed the study: one patient was withdrawn following admission for abdominal hysterectomy: a second, aged 59 years, developed mild heart failure whilst receiving atenolol. She made an uneventful recovery following withdrawal of atenolol, and her hypertension was subsequently controlled on bendrofluazide 10 mg daily. In the twelve remaining patients, blood pressure before atenolol therapy averaged 196-3/ 115-7 mmHg (26-1/15-4 kPa) in recumbency and heart rate 77-8 beats/min. Atenolol produced a highly significant reduction in blood pressure, in both supine and standing positions as well as in heart rate (Tables 3 and 4) 
Discussion
The present findings confirm that atenolol, like other 3-adrenoceptor antagonists, will produce a satisfactory reduction in arterial blood pressure when given chronically by mouth. Unlike propranolol, however, no dose-related reduction in blood pressure was identified. This confirms the findings of Myers et al. (1976) and Amery et al. (1976) . A further advantage of atenolol is that blood pressure control appears to be adequate on a single daily dose confirming claims made by Douglas-Jones and Cruickshank (1976) . Since compliance is one of the major problems in the management of hypertensive patients, a single 100 mg daily dose may confer significant advantages in clinical practice. It appears, however, that the full hypotensive action of atenolol takes at least 2 weeks to develop even though the majority of this is seen within 1 week of starting the treatment. However, like other 3-adrenoceptor antagonists, atenolol has predictable adverse effects which include Raynaud's phenomenon (Marshall, Roberts and Barritt, 1976) and heart failure. There were no statistically significant differences found between the mean values recorded during the three active treatments, except for weights on atenolol 50 mg b.d. and atenolol 100 mg b.d., week 2 (P<0 05).
